Will Pyxis Oncology Be Pfizer's Fourth Billion-Dollar Spinout?
Source: Life Science Leader
By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
It was late 2015 when Lara Sullivan, M.D., first called me. At the time she was a VP at Pfizer and working closely with Freda Lewis-Hall, M.D., then the company’s chief medical officer. From their vantage point, they could see this tremendous pipeline flow of assets—along with what got funded — and what did not. “There were a number of programs that had great clinical data, but unfortunately, did not have a development path within Pfizer,” she elaborates.
access the Magazine Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader
X
Subscribe to Life Science Leader
This website uses cookies to ensure you get the best experience on our website. Learn more